MISSISSAUGA, Ont. – Valeant Pharmaceuticals International Inc. (TSX:VRX) says it has acquired nearly 81 million shares of Cold-FX maker Afexa Life Sciences Inc., or nearly 74 per cent of the Edmonton drug maker, under a friendly takeover offer.
Get weekly money news
Get expert insights, Q&A on markets, housing, inflation, and personal finance information delivered to you every Saturday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.
Valeant said Tuesday it will extend its bid to Oct. 27 to acquire the rest of the shares and privatize Afexa.
The Toronto-area drug maker, formerly known as Biovail, wants to buy Afexa (TSX:FXA) to expand the company’s flu treatment sales globally.
Comments
Want to discuss? Please read our Commenting Policy first.